WASHINGTON, DC (April 2, 2017) - Adecto Pharmaceuticals, Inc., presented a poster on “Antibody targeting of ADAM8 for treatment of triple-negative breast cancer” at the 2017 AACR annual meeting. This poster described the characterization of Adecto’s novel panel of pre-clinical, highly specific anti-human ADAM8 mouse monoclonal antibodies, and specifically their ability to antagonize both the MP and DI activities of ADAM8. Data was presented on the isolation of Adecto’s two lead candidate therapeutic antibodies, ADP2 and ADP13, which cause significant reduction in growth of pre-existing primary tumors, extend recurrence-free survival and reduce metastasis in TNBC mouse models. ADAM8 inhibition was further shown to sensitize TNBC cells to Cisplatin, Doxorubicin and Paclitaxel, standard-of-care treatments for TNBC, suggesting a strategy for future clinical testing of Adecto’s ADAM8 antibody product. To access this poster, please follow the link below.